Evaluation of Occipital Nerve Stimulation in Intractable Occipital Neuralgias

Occipital Neuralgia Clinical Trial

— StimO  

Official title:

Evaluation of Occipital Nerve Stimulation in Intractable Occipital Neuralgias: a Multicentric, Controlled, Randomized Study

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03475797
• Other study ID #: RC17_0013
• Status: Terminated
• Phase: N/A
• Start date: April 20, 2018
• Est. completion date: September 3, 2021

Study information

• Verified date: October 2021
• Source: Nantes University Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Medically intractable pain caused by occipital neuralgia can be very difficult to control with traditional pain management. Peripheral nerve stimulation which is used in migraines and cluster headache can be an alternative for these patients with occipital neuralgias when medical treatment and traditional pain management have failed (drugs for neuropathic pain, infiltrations, psychobehavioral approaches and multidisciplinary approach in a pain center). Occipital nerve stimulation consists to put a lead subcutaneously in front of the occipital nerve and to connect the lead to a pulse generator. A retrospective study of 60 patients was conducted in Nantes University Hospital. The results were good with the Visual Analog Scale (VAS) decreased from 8.4 preoperatively to 2.85 postoperatively. The medical quantification scale (MQS) was reduced to about 50% (18 preoperatively versus 9.9 postoperatively). Stimulation was quiet stable over time with a mean follow-up of 24 months (range 6 to 72 months). The aim of StimO is to confirm this result through a national controlled randomized multicenter study where occipital nerve stimulation will be compared to the optimal medical management.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 22
• Est. completion date: September 3, 2021
• Est. primary completion date: June 26, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• Patients between 18 and 85 years old
• Chronic occipital neuralgias as defined by International Headache Society (IHS) more than 6 months with permanent pain associated or not with paroxysm
• Secondary occipital neuralgias (post-traumatic, post-surgery, major arthrosis, compression or lesion of the occipital nerve …)
• Chronic neuropathic pain according to the Neuropathic Pain Diagnostic Questionnaire (DN4 = 4)
• Maximum pain on VAS = 50/100
• Failure of medical treatment (association of neuropathic medication like antiepileptic and/or antidepressant and/or antalgic treatment like paracetamol, tramadol or morphine) and pain management in a pain Unit including multidisciplinary approach, physiotherapy, block test in C1-C2, radiofrequency rhizolysis, and/or corticosteroid infiltration of C2 according to the criteria defined by Health Authorities for spinal cord stimulation.
• Reduction of pain with Transcutaneous Electrical Nerve Stimulation (TENS) in occipital area
• Neurological examen has to be completed and must be normal except for the occipital neuralgia territory
• A negative pregnancy test for women with childbearing potential
• Women of childbearing potential must use appropriate method(s) of contraception during the clinical trial
• Patients must be capable of giving informed consent and must have signed informed consent
• Affiliation to an appropriate health insurance

Exclusion Criteria:

• Contraindication to the experimental medical devices
• Titanium related allergies
• Patients with contraindications to general anesthesia
• Complete anaesthesia in the C2/Great occipital nerve territory
• Drug or alcohol addiction
• Psychiatric disorders (psychiatric evaluation)
• Any medical or psychological problems which may interfere with a smooth conduction of the study protocol (e.g. cancer with a limited life expectancy)
• Need for intensive nursing care
• Difficulty in follow-up
• Pregnant or lactating women
• Women not using contraception
• Adults under a legal protection regime (guardianship, trusteeship, "sauvegarde de justice")
• Exclusion period for another study
• Simultaneous participation in another clinical trial except if that other trial does not affect the StimO study as approved and documented by the sponsor

Related Conditions & MeSH terms

• Neuralgia
• Occipital Neuralgia

Intervention

Device:
• Occipital nerve stimulation
Occipital nerve stimulation with percutaneous or surgical lead

Other:
• Optimal Medical Management
Optimal Medical Management according to what is done in routine clinical practice : drug, psychobehavioral approach, acupuncture, sophrology, etc.

Locations

Country	Name	City	State
France	CHU de Caen	Caen
France	CHU de Clermont-Ferrand	Clermont-Ferrand
France	Hôpitaux Civils de Colmar	Colmar
France	CHU Limoges	Limoges
France	Hôpital Pierre Wertheimer	Lyon
France	CHU de Nantes	Nantes
France	CHU de Nice	Nice
France	Hôpital Foch	Paris
France	Hôpital Lariboisière	Paris
France	CHU de Poitiers	Poitiers

Sponsors (1)

Lead Sponsor	Collaborator
Nantes University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of occipital nerve stimulation	Compare the decrease of pain (evaluated by visual analogic scale) after 6 months of treatment between the 2 groups (ONS / OMM)	6 months
Secondary	Decrease of medical treatment (i.e. decrease of Medication Quantification Scale (MQS) score) in the ONS group at 3 months	Evaluate the decrease of medical treatment (i.e. decrease of Medication Quantification Scale (MQS) score) after 3 months of occipital nerve stimulation in the ONS group	3 months
Secondary	Decrease of medical treatment (i.e. decrease of Medication Quantification Scale (MQS) score) in the ONS group at 6 months	Evaluate the decrease of medical treatment (i.e. decrease of Medication Quantification Scale (MQS) score) after 6 months of occipital nerve stimulation in the ONS group	6 months
Secondary	Maximum pain (using Visual Analogic Scale)	Comparison of maximum pain (using Visual Analogic Scale) between the 2 groups (ONS/OMM)	Up to 6 months
Secondary	Average pain (using Visual Analogic Scale)	Comparison of average pain (using Visual Analogic Scale) between the 2 groups (ONS/OMM)	Up to 6 months
Secondary	Relative decrease of pain (using Visual Analogic Scale) at 3 months	Comparison of the relative decrease of pain (using Visual Analogic Scale) at 3 months between the 2 groups (ONS/OMM)	3 months
Secondary	Relative decrease of pain (using Visual Analogic Scale) at 6 months	Comparison of the relative decrease of pain (using Visual Analogic Scale) at 6 months between the 2 groups (ONS/OMM)	6 months
Secondary	Efficacy of the treatment (using Migraine Disability Assessment (MIDAS) Test) at 3 months	Comparison of the efficacy of the treatment (using Migraine Disability Assessment (MIDAS) Test) at 3 months between the 2 groups (ONS/OMM)	3 months
Secondary	Efficacy of the treatment (using Migraine Disability Assessment (MIDAS) Test) at 6 months	Comparison of the efficacy of the treatment (using Migraine Disability Assessment (MIDAS) Test) at 6 months between the 2 groups (ONS/OMM)	6 months
Secondary	Quality of life (using EQ-5D-5L questionnaire)	Comparison of the quality of life (using EQ-5D-5L questionnaire) between the 2 groups (ONS/OMM)	Up to 6 months
Secondary	Quality of life (using Hamilton Anxiety and Depression (HAD) scale)	Comparison of the quality of life (using Hamilton Anxiety and Depression (HAD) scale) between the 2 groups (ONS/OMM)	Up to 6 months